JGH OPEN:丙氨酸转氨酶长期> 1000 IU / L的后果

2020-04-12 MedSci原创 MedSci原创

丙氨酸氨基转移酶(ALT)的明显升高是由基础疾病引起的,这些病理改变包括肝缺血,药物/毒素,病毒性肝炎,以及罕见的自身免疫性肝炎。

背景与目标:丙氨酸氨基转移酶(ALT)的明显升高是由基础疾病引起的,这些病理改变包括肝缺血,药物/毒素,病毒性肝炎,以及罕见的自身免疫性肝炎。本项研究的目的是确定导致ALT大于1000IU/L的病因相对发生率,以及临床预后的因素。

方法:研究人员在2013年1月至2015年12月之间,对澳大利亚所有大型教学医院网络中所有ALT水平高于1000IU/L的成年患者进行了一项回顾性队列研究。多变量logistic回归分析用于确定病因和死亡率的预测指标。

结果:有287名患者的ALT水平高于1000IU/L。最常见的原因是缺血(44%),药物/毒素(19%),胆道梗阻(16%)和病毒性肝炎(7%)。诊断为缺血性肝炎的独立预测因素包括:低血压(29.2; 8.2-104.7),冠状动脉疾病(12.9; 1.7–98.9),充血性心力衰竭(7.8; 1.2–49.2),糖尿病(7.4; 1.6–33.9),代谢性酸中毒(6.2; 2.0–19.4),γ-谷氨酰转移酶<135 IU / L(5.1; 1.5–17.6) )和白蛋白<34g/L(3.4; 1.1-11.0)。全天28天致死的独立危险因素包括:败血性休克(14.7; 4.3-50.7),代谢性酸中毒(7.3; 2.5-21.3),COPD病史(5.4; 1.6-17.8),心源性休克(4.3; 1.6–11.7),

结论:缺血性肝炎是ALT水平高于1000IU/L的最常见病因,并且与高死亡率相关。

原始出处:

Danny Con. Et al. Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort. journal of gastroenterology and hepatology.2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752045, encodeId=c8e31e52045e0, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Fri Jul 24 17:16:08 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728409, encodeId=c8131e28409c9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 23 01:16:08 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395467, encodeId=63fc139546ea3, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Apr 14 12:16:08 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1752045, encodeId=c8e31e52045e0, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Fri Jul 24 17:16:08 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728409, encodeId=c8131e28409c9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 23 01:16:08 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395467, encodeId=63fc139546ea3, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Apr 14 12:16:08 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2021-01-23 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1752045, encodeId=c8e31e52045e0, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Fri Jul 24 17:16:08 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728409, encodeId=c8131e28409c9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 23 01:16:08 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395467, encodeId=63fc139546ea3, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Apr 14 12:16:08 CST 2020, time=2020-04-14, status=1, ipAttribution=)]

相关资讯

上海试点免费为慢性肝炎患者家庭提供签约管理服务

记者在全国爱肝日到来之际从上海市疾控中心获悉:上海在全国率先开展慢性肝炎患者签约管理工作,已有27个试点社区免费为慢性肝炎患者家庭提供签约管理服务。

综述:慢性丙肝患者的规范化治疗

       我国是一个乙型肝炎(简称乙肝)大国,临床医师及公众对乙肝的认知度、警觉度均较高,而丙型肝炎(简称丙肝)却往往被忽视,以致其早期发现率和诊断率均较低。事实上,丙肝在世界范围呈广泛流行,是欧美及日本等国家终末期肝病的最主要原因。在我国一般人群中,抗-HCV阳性率也有0.43%。丙肝病毒(HCV)感染的慢性化率(50%~85%)远